跳至主要内容
临床试验/NL-OMON25015
NL-OMON25015尚未招募不适用

Minimal residual disease in peripheral blood compared to bone marrow in patients treated for acute myeloid leukemia

one0 个研究点目标入组 151 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
one
入组人数
151

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Patient with:
  • - a diagnosis of AML and related precursor neoplasms according to WHO 2008 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML), or
  • - acute leukemia’s of ambiguous lineage according to WHO 2008 or
  • - a diagnosis of refractory anemia with excess of blasts (MDS) and IPSS-R score > 4.5.
  • Treated according to HOVON clinical trials with intensive chemotherapy;
  • Age 18 yr or older;
  • A bone marrow aspiration has been scheduled;
  • WHO performance status 0, 1 or 2;
  • Written informed consent.

排除标准

  • Pregnant or lactating females;
  • Unwilling or not capable to use effective means of birth control.

研究者

发起方
one

相似试验